预约演示
更新于：2025-11-14
Nimustine Hydrochloride
盐酸尼莫司汀
更新于：2025-11-14
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C9H14Cl2N6O2 |
InChIKeyKPMKNHGAPDCYLP-UHFFFAOYSA-N |
CAS号55661-38-6 |
关联
11
项与 盐酸尼莫司汀 相关的临床试验JPRN-jRCT2021190003
Phase II multicenter investigator initiated trial of Convection-enhanced delivery of Nimustine Hydrochloride against brainstem gliomas - Convection-enhanced delivery of Nimustine Hydrochloride against brainstem gliomas
JPRN-jRCTs021180011
Phase II study of Convection-enhanced delivery of Nimustine Hydrochloride combined with systemic Temozolomide against recurrent gliomas at brainstem - ACNU/CED plus systemic TMZ against recurrent gliomas at brainstem: Phase II study
NCT02698280
Phase II Study of Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
100 项与 盐酸尼莫司汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸尼莫司汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸尼莫司汀 相关的专利（医药）
登录后查看更多信息
1,083
项与 盐酸尼莫司汀 相关的文献（医药）2025-06-01CANCER SCIENCE
A Multicenter Phase II Trial of Nimustine Hydrochloride Administered via Convection‐Enhanced Delivery in Children With DIPG
Article
作者: Chiba, Kentaro ; Arakawa, Yoshiki ; Sonoda, Yukihiko ; Mineharu, Yohei ; Takahashi, Fumiaki ; Shibahara, Ichiyo ; Saito, Ryuta ; Sato, Aya ; Kanamori, Masayuki ; Kumabe, Toshihiro ; Tominaga, Teiji ; Kinoshita, Manabu ; Matsuda, Kenichiro ; Aihara, Yasuo
ABSTRACT:
Diffuse intrinsic pontine glioma (DIPG) is a very challenging‐to‐treat pediatric malignant tumor, with a median survival time of < 12 months. Convection‐enhanced delivery (CED) allows for direct drug administration into the tumor site, showing potential as a novel therapeutic approach. This study evaluated the efficacy of CED of nimustine hydrochloride (ACNU) in children with DIPG. This phase 2, single‐arm, multicenter study enrolled patients aged 3–21 years and diagnosed with DIPG. The investigational treatment commenced 1 month after completing radiotherapy (local 50–60 Gy). The treatment involved stereotactic brain surgery for catheter placement, followed by ACNU administration via a CED catheter at a concentration of 0.75 mg/mL for 2–3 days until a cumulative dose of 7 (±0.3) mL was achieved. The primary endpoint was the 1‐year survival rate. From April 2018 to March 2020, 21 children were enrolled in the trial and treated, with 20 evaluable for the primary endpoint. The 1‐year survival rate from the start of radiotherapy was 60%, and the median survival time was 15 months. The response rate was analyzed in 20 patients, with one complete response (CR), six partial responses (PR), nine stable diseases, and four progressive diseases, resulting in a response rate of 35% (CR + PR). The CED of ACNU in the brainstem of children with DIPG after radiotherapy appears to be an effective therapeutic strategy. This approach warrants further development as a treatment for children with DIPG. This study is registered with jRCT (No. jRCT2021190003).
2025-03-04British journal of neurosurgery
Spontaneous Shrinkage of isocitrate dehydrogenase (IDH)-mutant astrocytoma caused by intra-tumoural cyst rupture: a case report
Article
作者: Tominaga, Teiji ; Suzuki, Ryutaro ; Watanabe, Mika ; Saito, Ryuta ; Kanamori, Masayuki ; Shimoda, Yoshiteru
BACKGROUND:
T2-fluid-attenuated inversion recovery (FLAIR) mismatch sign is a specific imaging finding of isocitrate dehydrogenase (IDH)-mutant astrocytomas. Histologically, a hypointense area on FLAIR images indicates the presence of microcysts. Here we report a case of IDH-mutant astrocytoma that shrunk spontaneously.
CASE DESCRIPTION:
A 26-year-old woman presented with a complaint of headache. Her magnetic resonance (MR) images revealed a lesion mass with a T2-FLAIR mismatch sign in the left frontal lobe. Subsequently, after 1 month, she was referred to our department, and we found that the lesion had unexpectedly shrunk; however, no further shrinkage was observed in the next 3 months. Furthermore, a biopsy was performed, and the results indicated a diagnosis of astrocytoma, IDH-mutant CNS WHO grade 3. Thus, she underwent subtotal resection. We found no neurological deficits in the patient, and she received 60 Gy of radiotherapy at the local site and chemotherapy with nimustine hydrochloride (ACNU), followed by the administration of ACNU every 8 weeks for 2 years. Overall, after 36 months of tumour resection, she was in good health and exhibited no recurrence. Notably, her histological and MR image findings suggested that the macroscopic cyst was formed by the fusion of microcysts, which is a characteristic feature of IDH-mutant astrocytoma with a T2-FLAIR mismatch sign, and that the tumour shrunk because of the rupture of the cyst in the Sylvian cistern.
CONCLUSION:
The present case report suggests that IDH-mutant astrocytoma cannot be ruled out even when the lesion shrinks spontaneously.
2025-01-01Drug information journal
Expanding Pharmaceutical Access Via Over the Counter Drugs
Letter
作者: Jouaneh, Terra Marie M. ; Jouaneh, Terra Marie M ; Miller, Brian J ; Miller, Brian J. ; Gowda, Vrushab
Abstract:
This commentary addresses the recent U.S. Food & Drug Administration (FDA) proposed rule to expand access to nonprescription drugs through additional conditions of nonprescription use (ACNU). It surveys the various pathways to market for pharmaceutical products, noting the distinct requirements for over-the-counter (OTC) products differentiating them from prescription products. It subsequently reviews the ACNU proposed rule, weighing its potential benefits against possible limitations. With a view towards the future, the ACNU proposed rule is acknowledged as part of a longstanding tradition to expand drug channels in a risk-stratified fashion with increasing clinical oversight to address in tandem increasing consumer risks. Finally, the proposed rule also serves as a potential prelude for a future behind the counter drug pathway.
3
项与 盐酸尼莫司汀 相关的新闻（医药）2025-11-11
·医路我伴
上市批准抗体药物偶联物免疫疗法
2025-04-22
·摩熵医药
申请上市抗体药物偶联物临床1期临床申请
2024-02-27
·米内网
上市批准申请上市医药出海核酸药物免疫疗法
100 项与 盐酸尼莫司汀 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性淋巴细胞白血病 | 中国 | 2002-07-25 | |
| 费城染色体阳性慢性粒细胞白血病 | 中国 | 2002-07-25 | |
| 脑癌 | 日本 | 1979-05-22 | |
| 慢性白血病 | 日本 | 1979-05-22 | |
| 结直肠癌 | 日本 | 1979-05-22 | |
| 肝癌 | 日本 | 1979-05-22 | |
| 肺癌 | 日本 | 1979-05-22 | |
| 淋巴瘤 | 日本 | 1979-05-22 | |
| 胃癌 | 日本 | 1979-05-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 21 | 繭鏇願構憲鏇衊窪構鹽(鹹築襯窪範構壓夢膚積) = 蓋淵襯鏇廠築壓壓淵築 衊觸齋築廠積鑰簾鑰齋 (顧願艱窪糧鹹壓鬱糧繭 ) 更多 | 积极 | 2022-06-02 | |||
临床1/2期 | 7 | 範選醖積繭構壓衊膚艱(鬱築積夢築蓋廠壓構艱) = One in 3 patients who received 0.5 mg/mL developed lacunar infarction 衊膚齋範鑰糧築窪憲遞 (鬱夢鹹積觸憲遞築獵淵 ) | 积极 | 2016-11-07 | |||
临床3期 | 535 | RT/ACNU | 醖膚構鏇遞積膚構構繭(獵壓觸簾鹽範窪鑰艱艱) = 醖膚膚艱醖鹽鬱廠艱壓 廠積夢網窪艱醖選鹹淵 (積鬱醖觸鹹壓鏇觸膚艱 ) | 积极 | 2015-11-09 | ||
RT/TMZ | 醖膚構鏇遞積膚構構繭(獵壓觸簾鹽範窪鑰艱艱) = 範窪夢構網願築鹹鬱獵 廠積夢網窪艱醖選鹹淵 (積鬱醖觸鹹壓鏇觸膚艱 ) | ||||||
临床1/2期 | - | 鹽網願膚製積鏇鬱齋窪(觸繭網鑰廠鏇繭壓鏇選) = Acute toxicity was mainly hematologic and was controllable 範構遞觸築鏇選積積齋 (鬱鬱選願構鏇襯夢鹽範 ) 更多 | 积极 | 2009-11-01 | |||
N/A | 151 | 蓋淵膚艱鏇壓艱膚齋網(夢衊構鑰膚窪艱蓋鹽齋) = 鹹選蓋獵糧鹽製獵鏇餘 積鏇醖願醖齋膚願鹹壓 (襯選顧積夢鹽顧夢淵鑰 ) | 积极 | 2008-05-20 | |||
N/A | 35 | 遞鬱製憲構廠繭糧餘鑰(鏇願醖蓋鏇艱糧鑰膚夢) = 淵鏇廠醖艱鹹膚糧顧糧 鬱顧範鏇餘築鑰範夢範 (鹹築鏇簾製糧廠糧構鬱 ) 更多 | 积极 | 2008-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用